Analyze Diet
Journal of veterinary internal medicine2002; 16(5); 588-592; doi: 10.1892/0891-6640(2002)0162.3.co;2

Antigen-specific antibodies in cerebrospinal fluid after intramuscular injection of ovalbumin in horses.

Abstract: Eighteen normal horses were assigned to 1 of 3 treatment groups to investigate the effects of IM or intrathecal (IT) administration of ovalbumin on serum and cerebrospinal fluid (CSF) antibody production. Horses of group 1 were injected intramuscularly with ovalbumin and adjuvant, while horses in treatment groups 2 and 3 received ovalbumin intrathecally or intravenously, followed by IM injection as in group 1. Serum and CSF antibody titers were tested in group I every 30 days for 4 months, while serum and CSF were collected in group 2 and 3 horses at postvaccination day 60. Horses of group 1 (IM) developed a serum antibody titer that peaked at postadministration day 60 (1:24,320 +/- 7,680) (mean +/- I SEM). Anti-ovalbumin antibodies were detected in CSF, and titers paralleled that of the serum, although at a much lower concentration (peak, 1:166 +/- 87). Horses of groups 2 and 3 developed significantly (P = .02) lower serum titers (1:720 and 1:2,067, respectively), but the difference in CSF titers did not achieve statistical significance (P = .06). The results confirm that antigen-specific antibody can be found in the CSF of horses in which antigen is not administered intrathecally. This may affect the interpretation of CSF analysis in diseases such as equine protozoal myeloencephalitis. Further, the findings suggest that IT injection of the soluble antigen ovalbumin induces a state of antigenic tolerance in the horse. The clinical significance of this finding remains unknown at this time.
Publication Date: 2002-09-27 PubMed ID: 12322711DOI: 10.1892/0891-6640(2002)0162.3.co;2Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Clinical Trial
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study examines the ways intramuscular or intrathecal administration of ovalbumin, a type of protein, impacts the production of antibodies in both the serum and cerebrospinal fluid (CSF) of horses. Results demonstrated that antibodies can be found in the CSF even when the antigen is not administered intrathecally.

Study Design and Methodology

  • The research involved eighteen normal horses which were divided into three separate groups for treatment.
  • The horses of group 1 were injected intramuscularly (IM) with ovalbumin and an adjuvant.
  • Horses in groups 2 and 3 were given ovalbumin either intrathecally (directly in the spinal canal) or intravenously, followed by an intramuscular injection as given to group 1.

Data Collection

  • In group 1, the researchers tested antibody titers in the serum and cerebrospinal fluid every 30 days for a period of four months.
  • In groups 2 and 3, the serum and cerebrospinal fluid were collected on the 60th day after vaccination.

Results of the Study

  • The horses in group 1 developed a serum antibody titer that peaked 60 days after administration.
  • The study noted anti-ovalbumin antibodies in the cerebrospinal fluid, which followed a similar trend to those in the serum, but at a much lower concentration.
  • Compared to group 1, horses in groups 2 and 3 developed significantly lower serum titers but the difference in CSF titers did not attain statistical significance.

Significance of the Findings

  • The study confirms the presence of antigen-specific antibodies in the CSF of horses irrespective of whether the antigen was administered intrathecally or not.
  • This discovery could potentially impact the interpretation of cerebrospinal fluid analysis in certain equine diseases like protozoal myeloencephalitis.
  • The experiment also suggests that the intrathecal injection of the soluble antigen ovalbumin might induce a state of antigenic tolerance in horses, though the clinical significance of this finding was not determined.

Cite This Article

APA
Furr M. (2002). Antigen-specific antibodies in cerebrospinal fluid after intramuscular injection of ovalbumin in horses. J Vet Intern Med, 16(5), 588-592. https://doi.org/10.1892/0891-6640(2002)0162.3.co;2

Publication

ISSN: 0891-6640
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 16
Issue: 5
Pages: 588-592

Researcher Affiliations

Furr, Martin
  • Marion duPont Scott Equine Medical Center, Virginia-Maryland Regional College of Veterinary Medicine, Leesburg 20176, USA. mfurr@vt.edu

MeSH Terms

  • Animals
  • Antibodies / cerebrospinal fluid
  • Antibodies / immunology
  • Antibody Specificity
  • Antigens / administration & dosage
  • Antigens / immunology
  • Female
  • Horses
  • Immunoglobulin G / cerebrospinal fluid
  • Immunoglobulin G / immunology
  • Injections, Intramuscular
  • Male
  • Ovalbumin / administration & dosage
  • Ovalbumin / immunology
  • Time Factors

Citations

This article has been cited 4 times.
  1. Johnson AL, Johnstone LK, Stefanovski D. Cerebrospinal fluid Lyme multiplex assay results are not diagnostic in horses with neuroborreliosis. J Vet Intern Med 2018 Mar;32(2):832-838.
    doi: 10.1111/jvim.15067pubmed: 29460492google scholar: lookup
  2. Reed SM, Furr M, Howe DK, Johnson AL, MacKay RJ, Morrow JK, Pusterla N, Witonsky S. Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite Biology, Diagnosis, Treatment, and Prevention. J Vet Intern Med 2016 Mar-Apr;30(2):491-502.
    doi: 10.1111/jvim.13834pubmed: 26857902google scholar: lookup
  3. Ranjithkumar M, Saravanan BC, Yadav SC, Kumar R, Singh R, Dey S. Neurological trypanosomiasis in quinapyramine sulfate-treated horses--a breach of the blood-brain barrier?. Trop Anim Health Prod 2014 Feb;46(2):371-7.
    doi: 10.1007/s11250-013-0498-9pubmed: 24197687google scholar: lookup
  4. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?. Neuro Oncol 2011 Jan;13(1):3-13.
    doi: 10.1093/neuonc/noq169pubmed: 21149252google scholar: lookup